# Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers

> **NCT05412173** · NA · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 37 (actual)

## Conditions studied

- Viral Infection
- COVID-19

## Interventions

- **DRUG:** Molnupiravir

## Key facts

- **NCT ID:** NCT05412173
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-22
- **Primary completion:** 2022-05-17
- **Final completion:** 2022-06-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05412173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05412173, "Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05412173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*